NASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $184.22 -15.49 (-7.75%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Revolution Medicines Stock (NASDAQ:RVMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$183.09▼$211.4150-Day Range$177.96▼$221.1552-Week Range$58.91▼$224.31Volume2.03 million shsAverage Volume2.78 million shsMarket Capitalization$39.55 billionP/E RatioN/ADividend YieldN/APrice Target$244.00Consensus RatingModerate Buy Company Overview Revolution Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target. Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D. These therapies are being studied in clinical trials, including as potential treatments for colorectal, pancreatic, lung and other cancers. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines serves the global biopharmaceutical and oncology research markets through its drug-discovery and clinical-development programs. The company is led by Mark A. Goldsmith, M.D., Ph.D., who serves as chairman and chief executive officer. Revolution Medicines does not currently market an approved commercial product.AI Generated. May Contain Errors. Read More Revolution Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreRVMD MarketRank™: 3.61774973147 of 5 starsRevolution Medicines scored higher than 72% of companies evaluated by MarketBeat, and ranked 241st out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 22 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRevolution Medicines has a consensus price target of $242.90, representing about 26.5% upside from its current price of $192.03.Amount of Analyst CoverageRevolution Medicines has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($8.94) to ($6.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -21.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -21.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 22.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.53% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 6.13.Change versus previous monthShort interest in Revolution Medicines has recently increased by 8.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.02 News SentimentRevolution Medicines has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Revolution Medicines this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows21 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,422,765.00 in company stock.Percentage Held by Insiders7.60% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Stock News HeadlinesRevolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNovember 4 at 4:02 PM | globenewswire.comRevolution Medicines (RVMD) Stock Forecast & Price TargetNovember 4 at 3:56 PM | tipranks.comWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.November 5 at 1:00 AM | Brownstone Research (Ad)Revolution Medicines (RVMD) Set to Post Quarterly Earnings on WednesdayNovember 3 at 3:10 AM | americanbankingnews.comCould Revolution Medicines Be a Millionaire-Maker Stock?October 29, 2026 | fool.comBillionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?October 27, 2026 | fool.comRevolution Medicines to Participate in November 2026 Investor ConferencesOctober 27, 2026 | globenewswire.comRevolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks UndervaluedOctober 24, 2026 | finance.yahoo.comSee More Headlines RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $79.65 at the beginning of the year. Since then, RVMD shares have increased by 141.1% and is now trading at $192.0290. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) released its earnings results on Wednesday, November, 4th. The company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.45. The company earned $197.56 million during the quarter, compared to analyst estimates of $25.58 million. Read the conference call transcript. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $231 million in an initial public offering on Thursday, February 13th 2020. The company issued 14,000,000 shares at a price of $16.00-$17.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include Assenagon Asset Management S.A. (1.02%), Pictet Asset Management Holding SA (0.47%), Candriam S.C.A. (0.21%) and Sumitomo Mitsui Trust Group Inc. (0.18%). Insiders that own company stock include Thilo Schroeder, Stephen Michael Kelsey, Mark A Goldsmith, Margaret A Horn, Jack Anders, Xiaolin Wang, Lin Wei, Alan B Sandler, Jeff Cislini, Sushil Patel, Barbara Weber, Elizabeth M Anderson and Lorence H Kim. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Intel (INTC), Marvell Technology (MRVL) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/04/2026Today11/05/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RVMD's financial health is in the Green zone, according to TradeSmith. RVMD has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RVMD CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees883Year Founded2014Price Target and Rating Average Price Target for Revolution Medicines$244.00 High Price Target$320.00 Low Price Target$82.00 Potential Upside/Downside+32.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.13 billion Net MarginsN/A Pretax MarginN/A Return on Equity-88.20% Return on Assets-57.85% Debt Debt-to-Equity Ratio0.40 Current Ratio11.38 Quick Ratio11.38 Sales & Book Value Annual Sales$11.58 million Price / Sales3,403.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.44 per share Price / Book21.79Miscellaneous Outstanding Shares214,340,000Free Float198,046,000Market Cap$39.41 billion OptionableOptionable Beta1.44 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RVMD) was last updated on 11/5/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredWhat the 1929 crash math means for retirees todayIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole unt...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get a...The Oxford Club | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
